Breast Cancer

CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer. 

The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.

CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.

Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.

A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.

Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.

CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer. 

Multigene testing for all woman diagnosed with breast cancer can be “extremely cost-effective.”

Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.

A 21-gene assay is effective in guiding the use of adjuvant chemotherapy in patients with early breast cancer.

Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.

A new analysis found overall survival may be worse for some male breast cancer patients.

The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well.

The addition of the PARP inhibitor veliparib to carboplatin  and paclitaxel offered significant improvement to patients with HER2-negative breast cancer.

Remarkable gains have been made in breast cancer outcomes; however, racial disparities have contributed to breast cancer incidence.

A new study found men with breast cancer have higher mortality compared with women, possibly due to lack of awareness.

Two studies from ESMO have potentially found treatments which can improve survival in HR-positive breast cancer.

Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor–positive breast cancer.

Previous studies have found evidence onion and garlic may help prevent prostate, lung, and gastric cancers, but there was previously no definite association found between these foods and breast cancer.

A recent study found that women with early-stage breast cancer experienced atrial fibrillation in the first and fifth years following diagnosis.

African American women are less likely to receive care from leading specialists at Comprehensive Cancer Care centers, but seeking opinions from one can improve outcomes in breast cancer.

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor–positive breast cancer.

The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small.

Many clinical trials in breast and endometrial cancers are underway and recruiting patients.